LIF and neoplasm: Specifically, breast (23–25), ovarian (26), pancreatic (27), and nasopharyngeal cancers (28), have demonstrated that LIF overexpression by tumours contributes to tumor growth and metastasis as mediated by the STAT3 pathway.